研究单位：[1]Hoffmann-La Roche[2]Cancer Hospital Chinese Academy of Medical Sciences.,Beijing,China,100021[3]Sichuan Provincial Cancer Hospital,Chengdu,China,610041[4]Harbin Medical University Cancer Hospital,Harbin,China,150081[5]Shandong Cancer Hospital,Jinan,China,250117[6]Guangxi Cancer Hospital of Guangxi Medical University,Nanning,China,530021[7]First Affiliated Hospital of Medical College of Xi''an Jiaotong University,Xi''an,China,710061
This is a multicenter, observational cohort study in China with both primary prospective data collection and retrospective collection of prior treatment information from medical records, which enrolls and follows patients who are newly diagnosed with unresectable stage IIIB/IIIC/IV Non-Small-Cell Lung Cancer (NSCLC) in the selected sites. This study aims to describe the clinical practice and long-term survival benefits of patients newly diagnosed with unresectable stage IIIB/IIIC/IV NSCLC. The study also seeks to explore the condition of biomarker tests utilization, and to assess potential economic impact on patients in the real world. The safety related events will also be summarized in this study.
